8-K 1 inb8kjun28_2004.txt INTEGRATED BIOPHARMA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2004 Integrated BioPharma, Inc. -------------------------- (Exact name of registrant as specified in its charter) Delaware 000-28876 22-2407475 -------- --------- ---------- (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation or organization) Identification No.) 225 Long Avenue Hillside, New Jersey 07205 -------------------- ----- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (973) 926-0816 Not Applicable (Former name or former address, if changed since last report) Item 5. Other Events and Regulation FD Disclosure. On June 25, 2004, Integrated BioPharma, Inc., a Delaware corporation (the "Company"), issued a press release announcing its discovery that its common stock had been listed without its knowledge, consent or authority on a German stock exchange. The press release is attached as an exhibit to this Report. Item 7. Financial Statements and Exhibits (c) Exhibits. Exhibit No. Description 99.1 Press Release issued by Integrated BioPharma, Inc. on June 25, 2004 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: June 28, 2004 INTEGRATED BIOPHARMA, INC. By: /s/ Eric Friedman Eric Friedman Vice President and Chief Financial Officer Exhibit Index Exhibit No. Description 99.1 Press Release issued by Integrated BioPharma, Inc. on June 25, 2004